Inhibition of Aβ42 oligomerization in yeast by a PICALM ortholog and certain FDA approved drugs

@inproceedings{Park2016InhibitionOA,
  title={Inhibition of Aβ42 oligomerization in yeast by a PICALM
ortholog and certain FDA approved drugs },
  author={Sei-Kyoung Park and Kiira Ratia and Mariam A. Ba and Maria L. Valencik and Susan W Liebman},
  booktitle={Microbial cell},
  year={2016}
}
The formation of small Aβ42 oligomers has been implicated as a toxic species in Alzheimer disease (AD). In strong support of this hypothesis we found that overexpression of Yap1802, the yeast ortholog of the human AD risk factor, phosphatidylinositol binding clathrin assembly protein (PICALM), reduced oligomerization of Aβ42 fused to a reporter in yeast. Thus we used the Aβ42-reporter system to identify drugs that could be developed into therapies that prevent or arrest AD. From a screen of 1… CONTINUE READING